Skip to main content

Advertisement

Table 2 Outcomes of patients with CRE infections who received ceftazidime-avibactam compared with comparative group (received different CRE specific antibiotics)

From: Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae

Outcome Ceftazidime/Avibactam group n = 10 (%) Comparative group n = 28 (%) P value
Clinical remission 8 (80) 15 (53.6) 0.14
Clinical cure without relapse or 4 (40) 11 (39) > 0.99
death within 30 days
 30 days all-cause mortality 5 (50) 16 (57.1) 0.7
 Attributable mortality to CRE 2 (20) 11 (39.3) 0.27
 Length of stay, median (IQR), days 69.5 (47.5–96) 40.5 (22–79.5) 0.07
 30-days relapse of the same isolate 2 (20) 1 (3.6) 0.1
 Time to clearance of bacteremia, 4 (3–5) 5 (3–7) 0.65
median (IQR), days
  1. CRE Carbapenem-resistant Enterobacteriaceae, IQR Interquartile range